Mechanism of Action of Hormones That Act on Nuclear Receptors

Williams Textbook of Endocrinology, Twelfth Edition

Volumn , Issue , 2011, Pages 51-61

  Lazar, Mitchell A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887798801     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0324-5.00004-3     Document Type: Chapter

References (77)

1. P Chambon (2005) The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 19 1418-1428.
2. RM Evans (2005) The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19 1429-1438.
3. BW O’Malley (2005) A life-long search for the molecular pathways of steroid hormone action. Mol Endocrinol 19 1402-1411.
4. WE Visser, EC Friesema, J Jansen, et al. (2008) Thyroid hormone transport in and out of cells. Trends Endocrinol Metab 19 50-56.
5. H Heuer and TJ Visser (2009) Minireview: pathophysiological importance of thyroid hormone transporters. Endocrinology 150 1078-1083.
6. H Escriva, F Delaunay and V Laudet (2000) Ligand binding and nuclear receptor evolution. Bioessays 22 717-727.
7. JL Arriza, C Weinberger, G Cerelli, et al. (1987) Cloning of human mineralocorticoid receptor complementary cDNA: structure and functional kinship with the glucocorticoid receptor. Science 237 268-275.
8. AK Roy, RK Tyagi, CS Song, et al. (2001) Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci 949 44-57.
9. P Germain, P Chambon, G Eichele, et al. (2006) International Union of Pharmacology: LX. Retinoic acid receptors. Pharmacol Rev 58 712-725.
10. P Germain, P Chambon, G Eichele, et al. (2006) International Union of Pharmacology: LXIII. Retinoid X receptors. Pharmacol Rev 58 760-772.
11. L Michalik, J Auwerx, JP Berger, et al. (2006) International Union of Pharmacology: LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58 726-741.
12. BM Forman, J Chen and RM Evans (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94 4312-4317.
13. K Yu, W Bayonea, CB Kallen, et al. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270 23975-23983.
14. O Ziouzenkova, S Perrey, L Asatryan, et al. (2003) Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100 2730-2735.
15. I Issemann and S Green (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 645-650.
16. GD Barish, VA Narkar and RM Evans (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116 590-597.
17. SM Rangwala and MA Lazar (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25 331-336.
18. BM Forman, P Tontonoz, J Chen, et al. (1995) 15-Deoxy, delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARg. Cell 83 803-812.
19. SA Kliewer, JM Lenhard, TM Willson, et al. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 813-819.
20. JM Lehmann, LB Moore, TA Smith-Oliver, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor g (PPARg). J Biol Chem 270 12953-12956.
21. P Tontonoz and DJ Mangelsdorf (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17 985-993.
22. DD Moore, S Kato, W Xie, et al. (2006) International Union of Pharmacology: LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 58 742-759.
23. G Benoit, A Cooney, V Giguere, et al. (2006) International Union of Pharmacology: LXVI. Orphan nuclear receptors. Pharmacol Rev 58 798-836.
24. N Preitner, F Damiola, L Lopez-Molina, et al. (2002) The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110 251-260.
25. S Raghuram, KR Stayrook, P Huang, et al. (2007) Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol 14 1207-1213.
26. L Yin, N Wu, JC Curtin, et al. (2007) Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 318 1786-1789.
27. NZ Lu and JA Cidlowski (2004) The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci 1024 102-123.
28. J Zhang and MA Lazar (2000) The mechanism of action of thyroid hormone receptors. Annu Rev Physiol 62 439-466.
29. JC Achermann and JL Jameson (1999) Fertility and infertility: genetic contributions from the hypothalamic-pituitary-gonadal axis. Mol Endocrinol 13 812-818.
30. W Seol, HS Choi and DD Moore (1996) An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 272 1336-1339.
31. M Gurnell and VK Chatterjee (2004) Nuclear receptors in disease: thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors. Essays Biochem 40 169-189.
32. DM Niu, B Hwang, CM Tiu, et al. (2004) Contributions of bone maturation measurements to the differential diagnosis of neonatal transient hypothyroidism versus dyshormonogenetic congenital hypothyroidism. Acta Paediatr 93 1301-1306.
33. MJ McPhaul (2002) Molecular defects of the androgen receptor. Recent Prog Horm Res 57 181-194.
34. M Palermo, M Quinkler and PM Stewart (2004) Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metabol 48 687-696.
35. PM Stewart and ZS Krozowski (1999) 11 Beta-hydroxysteroid dehydrogenase. Vitam Horm 57 249-324.
36. D Moras and H Gronemeyer (1998) The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10 384-391.
37. RV Weatherman, RJ Fletterick and TS Scanlan (1999) Nuclear receptor ligands and ligand-binding domains. Annu Rev Biochem 68 559-581.
38. K Umesono, KK Murakami, CC Thompson, et al. (1991) Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65 1255-1266.
39. F Rastinejad, T Perlmann, RM Evans, et al. (1995) Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375 203-211.
40. V Chandra, P Huang, Y Hamuro, et al. (2008) Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on. DNA. Nature 456 350-356.
41. JS Carroll, CA Meyer, J Song, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38 1289-1297.
42. CY Lin, VB Vega, JS Thomsen, et al. (2007) Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 3 e87.
43. EC Bolton, AY So, C Chaivorapol, et al. (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 21 2005-2017.
44. Q Wang, W Li, XS Liu, et al. (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27 380-392.
45. JC Wang, MK Derynck, DF Nonaka, et al. (2004) Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci U S A 101 15603-15608.
46. MI Lefterova, Y Zhang, DJ Steger, et al. (2008) PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev 22 2941-2952.
47. R Nielsen, TA Pedersen, D Hagenbeek, et al. (2008) Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev 22 2953-2967.
48. RG Roeder (1998) Role of general and gene-specific cofactors in the regulation of eukaryotic transcription. Cold Spring Harb Symp Quant Biol 63 201-218.
49. S Halachmi, E Marden, G Martin, et al. (1994) Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264 1455-1458.
50. CL Smith and BW O’Malley (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 45-71.
51. W Feng, RC Ribieiro, RL Wagner, et al. (1998) Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 1747-1749.
52. RT Nolte, GB Wisely, S Westin, et al. (1998) Ligand binding and co-activator assembly of the peroxisome prolierator-activated receptor-gamma. Nature 395 137-143.
53. AK Shiau, D Barstad, PM Loria, et al. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
54. DM Heery, E Kalkhoven, S Hoare, et al. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 733-736.
55. W Fischle, Y Wang and CD Allis (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15 172-183.
56. CK Glass, DW Rose and MG Rosenfeld (1997) Nuclear receptor coactivators. Curr Opin Cell Biol 9 222-232.
57. S Aoyagi, KW Trotter and TK Archer (2005) ATP-dependent chromatin remodeling complexes and their role in nuclear receptor-dependent transcription in vivo. Vitam Horm 70 281-307.
58. M Ito, CX Yuan, S Malik, et al. (1999) Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 3 361-370.
59. C Rachez, Z Suidan, J Ward, et al. (1998) A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12 1787-1800.
60. Y Shang, X Hu, J DiRenzo, et al. (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843-852.
61. X Hu and MA Lazar (2000) Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab 11 6-10.
62. ML Privalsky (2004) The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66 315-360.
63. X Hu and MA Lazar (1999) The CoRNR motif contols the recruitment of corepressors to nuclear hormone receptors. Nature 402 93-96.
64. CK Glass and MG Rosenfeld (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14 121-141.
65. T Ishizuka and MA Lazar (2005) The nuclear receptor corepressor deacetylase activating domain is essential for repression by thyroid hormone receptor. Mol Endocrinol 19 1443-1451.
66. T Alenghat, K Meyers, SE Mullican, et al. (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456 997-1000.
67. MA Lazar (2003) Thyroid hormone action: a binding contract. J Clin Invest 112 497-499.
68. MI Chiamolera and FE Wondisford (2009) Minireview: thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. Endocrinology 150 1091-1096.
69. R Kumar and EB Thompson (2003) Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Mol Endocrinol 17 1-10.
70. D Shao and MA Lazar (1999) Modulating nuclear receptor function: may the phos be with you. J Clin Invest 103 1617-1618.
71. SJ Han, DM Lonard and BW O’Malley (2009) Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol Metab 20 8-15.
72. H Gronemeyer, JA Gustafsson and V Laudet (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3 950-964.
73. AL Bookout, Y Jeong, M Downes, et al. (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126 789-799.
74. X Yang, M Downes, RT Yu, et al. (2006) Nuclear receptor expression links the circadian clock to metabolism. Cell 126 801-810.
75. M Lupien, J Eeckhoute, CA Meyer, et al. (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132 958-970.
76. CK Osborne, H Zaho and SA Fuqua (2000) Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18 3172-3186.
77. Y Shang and M Brown (2002) Molecular determinants for the tissue specificity of SERMs. Science 295 2465-2468.